Succession planning is a critical aspect of managing small, closely held businesses, as the unexpected departure of a key leader can significantly disrupt operations and challenge the business's legal...
Entering into a letter of intent for an office lease agreement? Consult our playbook for valuable key provisions, alternative language provisions, and guidance for both landlords and tenants. Download...
In the complex world of M&A transactions, transition services agreements (TSAs) serve as critical bridges between deal closing and operational independence thus creating stability during organizational...
This practice note covers key legal and regulatory issues to evaluate, questions to ask, and documents to review in medical device or diagnostic technology deals, including M&A, investments, financings...
FTC Chair Lina Khan told a conference of the American Medical Association on February 14, 2024, that the healthcare market is under the microscope in the Commission’s push for greater competition across the economy. Recent efforts by the FTC in this space include requesting public comment on how powerful “middlemen” in the generic drug market may contribute to shortages of these drugs. The agency also announced a March 5 virtual workshop to examine the role of private equity’s investment in healthcare markets. Additionally, the FTC issued a recent comment supporting the government’s right to “march in” to invalidate a patent if the patent holder is charging an excessive price on a patented drug developed with taxpayer-funded research.
The Antitrust Agency Developments Tracker covers these developments and other FTC and DOJ non-case-related efforts, policy statements, and goings-on at the agencies.
READ NOW »
Related Content
Practical Guidance Updates Featuring the latest updates from your Practical Guidance account.
PRACTICAL GUIDANCE CUSTOMER EMAIL EDITION ON THE WEB
Experience results today with practical guidance, legal research, and data-driven insights—all in one place.Experience Lexis+
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.